Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the recipient of a significant growth in short interest in January. As of January 29th, there was short interest totalling 1,910,000 shares, a growth of 20.9% from the January 14th total of 1,580,000 shares. Based on an average daily volume of 447,900 shares, the days-to-cover ratio is currently 4.3 days. Currently, 7.8% of the shares of the stock are sold short.
VYGR opened at $7.33 on Wednesday. The stock’s 50-day moving average price is $7.92 and its 200 day moving average price is $9.73. Voyager Therapeutics has a 12-month low of $6.26 and a 12-month high of $14.62. The firm has a market cap of $274.63 million, a price-to-earnings ratio of -4.47 and a beta of 1.80.
In related news, CFO Allison Dorval sold 2,942 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $8.62, for a total transaction of $25,360.04. Following the completion of the sale, the chief financial officer now directly owns 49,080 shares in the company, valued at $423,069.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andre Turenne sold 10,443 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $8.62, for a total value of $90,018.66. Following the sale, the chief executive officer now owns 156,352 shares of the company’s stock, valued at $1,347,754.24. The disclosure for this sale can be found here. 23.90% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Aigen Investment Management LP acquired a new position in Voyager Therapeutics during the 3rd quarter worth about $77,000. DekaBank Deutsche Girozentrale acquired a new position in Voyager Therapeutics during the 3rd quarter worth about $104,000. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Voyager Therapeutics by 2.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 123,338 shares of the company’s stock worth $1,316,000 after acquiring an additional 2,783 shares in the last quarter. Federated Hermes Inc. lifted its stake in Voyager Therapeutics by 19.0% during the 3rd quarter. Federated Hermes Inc. now owns 309,378 shares of the company’s stock worth $3,301,000 after acquiring an additional 49,435 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC lifted its stake in Voyager Therapeutics by 12.0% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 33,168 shares of the company’s stock worth $354,000 after acquiring an additional 3,552 shares in the last quarter. 78.79% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have issued reports on VYGR shares. Zacks Investment Research cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 6th. Canaccord Genuity restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Wednesday, January 13th. Cantor Fitzgerald cut Voyager Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $15.00 to $10.00 in a report on Wednesday, December 23rd. Morgan Stanley dropped their target price on Voyager Therapeutics from $13.00 to $7.00 and set a “hold” rating for the company in a report on Wednesday, February 3rd. Finally, HC Wainwright started coverage on Voyager Therapeutics in a report on Monday, January 25th. They issued a “buy” rating and a $12.00 target price for the company. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Voyager Therapeutics presently has an average rating of “Hold” and an average price target of $12.29.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson’s disease.
Read More: QQQ ETF
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]